GlassScriptPhysician profile
Hadas Skupsky
NPI 1093032658
$5,647.37
in general payments reported to CMS, 2019-2025
31 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.44 · 2020: $18.24 · 2021: $337 · 2022: $725 · 2023: $1,647 · 2024: $1,357 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.77 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $656.03 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $648.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $511.07 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $370.02 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $305.50 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $263.18 | 2021-2025 | Bimzelx |
| Amgen INC. | $195.39 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $157.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.73 | 2022-2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $146.83 | 2021-2024 | Blu-U, Odomzo, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $131.33 | 2022-2024 | Sotyktu |
| Incyte Corporation | $123.69 | 2021-2025 | Opzelura |
| Pfizer INC. | $114.20 | 2023-2025 | |
| Caris Mpi, INC. | $110.90 | 2025 | Mi Cancer Seek |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $107.51 | 2023 | Vtama |
| Merz North America, INC. | $103.74 | 2020-2024 | |
| Almirall LLC | $73.76 | 2022-2023 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $64.30 | 2019-2025 | |
| Galderma Laboratories, L.P. | $59.68 | 2022-2025 | Aklief |
| Biofrontera INC. | $46.50 | 2024-2025 | Rhodoled Xl, Ameluz, Xepi |
| Journey Medical Corporation | $35.49 | 2022-2025 | |
| Allergan, INC. | $34.32 | 2022 | |
| Blueprint Medicines Corporation | $29.31 | 2023 | Ayvakit |
| Lifenet Health | $25.57 | 2023 | |
| Fresenius Kabi USA, LLC | $25.11 | 2023 | Idacio |
| Lnhc, INC | $24.34 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $23.77 | 2023 | Poteligeo |
| Organon LLC | $20.20 | 2025 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $19.30 | 2024 | Fraxel, Clear & Brilliant |
| Helsinn Therapeutics (U.S.), INC. | $19.30 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadas Skupsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.